- Home
- PSTL vs CCCC Comparison
PSTL vs CCCC Comparison
Compare PSTL & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSTL | CCCC |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 329.8M | 240.3M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PSTL | CCCC |
|---|---|---|
| Price | $16.06 | $2.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $17.58 | $7.25 |
| AVG Volume (30 Days) | 213.1K | ★ 2.0M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.01% | N/A |
| EPS Growth | ★ 508.95 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $91,195,000.00 | $30,108,000.00 |
| Revenue This Year | $24.54 | N/A |
| Revenue Next Year | $12.00 | N/A |
| P/E Ratio | $33.36 | ★ N/A |
| Revenue Growth | ★ 26.65 | N/A |
| 52 Week Low | $12.26 | $1.09 |
| 52 Week High | $16.50 | $4.26 |
Technical Indicators
Market Signals| Indicator | PSTL | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 65.22 | 36.94 |
| Support Level | $15.97 | $2.00 |
| Resistance Level | $16.39 | $2.69 |
| Average True Range (ATR) | 0.30 | 0.18 |
| MACD | 0.09 | -0.07 |
| Stochastic Oscillator | 74.46 | 10.06 |
Price Performance
Historical ComparisonAbout PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.